))
CAR-T vs bispecifics: replacing ASCT in myeloma
Manage episode 302503233 series 2838329
Inhoud geleverd door VJHemOnc. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door VJHemOnc of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades; however, high-risk patients still have poor outcomes. Many bispecific antibody therapies are currently under investigation for the treatment of myeloma, such as blinatumomab, teclistamab, talquetamab and cevostamab, and the chimeric antigen receptor (CAR) T-cell therapy, idecabtagene vicleucel, became the first CAR-T therapy to receive FDA approval for the treatment of multiple myeloma in March 2021. With CAR-T and bispecific antibodies demonstrating deep and sustained remissions, the role of ASCT in the future treatment of myeloma has become a subject of debate.
In this podcast, Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, and Parameswaran Hari, MD, MRCP, MS, of the Froedtert Hospital Cancer Center, Milwaukee, WI, discuss the benefits and drawbacks of the two immunotherapeutic modalities, CAR-T and bispecific antibodies as a replacement for ASCT in multiple myeloma.
200 afleveringen
Delen
